The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF

FEBS Letters

Volumn 582, Issue 30, 2008, Pages 4125-4130

  Yoshida, Takeshi ^a   Okamoto, Isamu ^a   Iwasa, Tsutomu ^a   Fukuoka, Masahiro ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; EGF receptor; Heparin binding EGF like growth factor; Matuzumab; Non small cell lung cancer

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 57049094352     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.11.010     Document Type: Article

References (35)

1. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
2. El-Abaseri T.B., Putta S., and Hansen L.A. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 27 (2006) 225-231
3. Xu K.P., Ding Y., Ling J., Dong Z., and Yu F.S. Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 45 (2004) 813-820
4. King C.R., Borrello I., Porter L., Comoglio P., and Schlessinger J. Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock. Oncogene 4 (1989) 13-18
5. Chen C.H., Cheng T.H., Lin H., Shih N.L., Chen Y.L., Chen Y.S., Cheng C.F., Lian W.S., Meng T.C., Chiu W.T., and Chen J.J. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol. Pharmacol. 69 (2006) 1347-1355
6. Park C.M., Park M.J., Kwak H.J., Lee H.C., Kim M.S., Lee S.H., Park I.C., Rhee C.H., and Hong S.I. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 66 (2006) 8511-8519
7. Wang F., Liu R., Lee S.W., Sloss C.M., Couget J., and Cusack J.C. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26 (2007) 2006-2016
8. Winograd-Katz S.E., and Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25 (2006) 7381-7390
9. Benhar M., Engelberg D., and Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 21 (2002) 8723-8731
10. Johnson F.M., Saigal B., and Donato N.J. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J. Cell. Physiol. 205 (2005) 218-227
11. Van Schaeybroeck S., Kyula J., Kelly D.M., Karaiskou-McCaul A., Stokesberry S.A., Van Cutsem E., Longley D.B., and Johnston P.G. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol. Cancer Ther. 5 (2006) 1154-1165
12. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56 (1987) 881-914
13. Klapper L.N., Kirschbaum M.H., Sela M., and Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77 (2000) 25-79
14. Di Marco E., Pierce J.H., Fleming T.P., Kraus M.H., Molloy C.J., Aaronson S.A., and Di Fiore P.P. Autocrine interaction between TGFα and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4 (1989) 831-838
15. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13 (1999) 2905-2927
16. Goswami A., Ranganathan P., and Rangnekar V.M. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res. 66 (2006) 2889-2892
17. Katz M., Amit I., and Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 1773 (2007) 1161-1176
18. Roberts P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
19. Yoshida T., Okamoto I., Okabe T., Iwasa T., Satoh T., Nishio K., Fukuoka M., and Nakagawa K. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int. J. Cancer 122 (2008) 1530-1538
20. Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., and Nakagawa K. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 67 (2007) 2046-2053
21. Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65 (2005) 2825-2831
22. Akashi Y., Okamoto I., Iwasa T., Yoshida T., Suzuki M., Hatashita E., Yamada Y., Satoh T., Fukuoka M., Ono K., and Nakagawa K. The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo. Br. J. Cancer 96 (2007) 1532-1539
23. Higashiyama S., and Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim. Biophys. Acta 1751 (2005) 110-117
24. Miyamoto S., Yagi H., Yotsumoto F., Kawarabayashi T., and Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci. 97 (2006) 341-347
25. Ono M., Raab G., Lau K., Abraham J.A., and Klagsbrun M. Purification and characterization of transmembrane forms of heparin-binding EGF-like growth factor. J. Biol. Chem. 269 (1994) 31315-31321
26. Mitamura T., Higashiyama S., Taniguchi N., Klagsbrun M., and Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J. Biol. Chem. 270 (1995) 1015-1019
27. Suganuma K., Kubota T., Saikawa Y., Abe S., Otani Y., Furukawa T., Kumai K., Hasegawa H., Watanabe M., Kitajima M., Nakayama H., and Okabe H. Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci. 94 (2003) 355-359
28. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 (2005) 301-311
29. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
30. Kleespies A., Ischenko I., Eichhorn M.E., Seeliger H., Amendt C., Mantell O., Jauch K.W., and Bruns C.J. Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine. Clin. Cancer Res. 14 (2008) 5426-5436
31. Graeven U., Kremer B., Sudhoff T., Killing B., Rojo F., Weber D., Tillner J., Unal C., and Schmiegel W. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94 (2006) 1293-1299
32. Rao S., Starling N., Cunningham D., Benson M., Wotherspoon A., Lupfert C., Kurek R., Oates J., Baselga J., and Hill A. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br. J. Cancer 99 (2008) 868-874
33. Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., Rosen O., Tillner J., Kovar A., Braun A.H., Trarbach T., Seeber S., Harstrick A., and Baselga J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22 (2004) 175-184
34. Salazar R., Tabernero J., Rojo F., Jimenez E., Montaner I., Casado E., Sala G., Tillner J., Malik R., and Baselga J. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). J. Clin. Oncol. 22 Suppl. 14 (2004) 127
35. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000) 4885-4892